Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70

四分位间距 医学 安慰剂 内科学 载脂蛋白B 胆固醇 他汀类 内分泌学 高密度脂蛋白 脂蛋白 胃肠病学 病理 替代医学
作者
Brian Bergmark,Nicholas Marston,Candace Bramson,M. Curto,Vesper Ramos,Alexandra Jevne,Julia Kuder,Jeong‐Gun Park,Sabina A. Murphy,Subodh Verma,Wojciech Wojakowski,Steven G. Terra,Marc S. Sabatine,Stephen D. Wiviott,Diane Carbonneau,Raphael Poulin-Robitaille,Jeffrey D. Wayne,Keung Lee,Samuel Mujica Trenche,Petros Dzongowski,Daniel Gaudet,Joanna Van,Dilawar Ajani,Harold Bays,John O’Mahony,Adam Janas,John Scott,Moustafa Ashraf Moustafa,Thomas Ransom,Sabrina Benjamin,Naresh Aggarwal,Paweł Bogdański,Douglas G Friars,Robert Schlosser,Bogusław Okopień,Madhusudan Budhraja,Lawrence Feld,Leslie J. Klaff,Guy Tellier,Giuseppe Mazza,I Wierzbicka,Ewa Jazwinska-Tarnawska,Fernando Boccalandro,Julio Rosenstock,Elizabeth Marquez,Kim Barbel-Johnson,Katarzyna Madziarska,K W Heaton,Jean‐Claude Tardif,John Rubino,Miguel Á. Treviño,Katie Moriarty,Anil Gupta,Wojciech Wojakowski,James L. Fidelholtz,Dhiraj Gupta,Hani Al‐Asaad,Shane Christensen,Parag K Shah,Stephanie Li,Mark Sherman,Andre Frechette,Cecilia Arango,Alan Egan,Sunny Srivastava,Archna Bajaj,Carlos Ince,Aleksander Żurakowski
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:145 (18): 1377-1386 被引量:90
标识
DOI:10.1161/circulationaha.122.059266
摘要

Genetic loss-of-function variants in ANGPTL3 are associated with lower levels of plasma lipids. Vupanorsen is a hepatically targeted antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis.Adults with non-high-density lipoprotein cholesterol (non-HDL-C) ≥100 mg/dL and triglycerides 150 to 500 mg/dL on statin therapy were randomized in a double-blind fashion to placebo or 1 of 7 vupanorsen dose regimens (80, 120, or 160 mg SC every 4 weeks, or 60, 80, 120, or 160 mg SC every 2 weeks). The primary end point was placebo-adjusted percentage change from baseline in non-HDL-C at 24 weeks. Secondary end points included placebo-adjusted percentage changes from baseline in triglycerides, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and ANGPTL3.Two hundred eighty-six subjects were randomized: 44 to placebo and 242 to vupanorsen. The median age was 64 (interquartile range, 58-69) years, 44% were female, the median non-HDL-C was 132.4 (interquartile range, 118.0-154.1) mg/dL, and the median triglycerides were 216.2 (interquartile range, 181.4-270.4) mg/dL. Vupanorsen resulted in significant decreases from baseline over placebo in non-HDL-C ranging from 22.0% in the 60 mg every 2 weeks arm to 27.7% in the 80 mg every 2 weeks arm (all P<0.001 for all doses). There were dose-dependent reductions in triglycerides that ranged from 41.3% to 56.8% (all P<0.001). The effects on LDL-C and ApoB were more modest (7.9%-16.0% and 6.0%-15.1%, respectively) and without a clear dose-response relationship' and only the higher reductions achieved statistical significance. ANGPTL3 levels were decreased in a dose-dependent manner by 69.9% to 95.2% (all P<0.001). There were no confirmed instances of significant decline in renal function or platelet count with vupanorsen. Injection site reactions and >3× elevations of alanine aminotransferase or aspartate aminotransferase were more common at higher total monthly doses (up to 33.3% and 44.4%, respectively), and there was a dose-dependent increase in hepatic fat fraction (up to 76%).Vupanorsen administered at monthly equivalent doses from 80 to 320 mg significantly reduced non-HDL-C and additional lipid parameters. Injection site reactions and liver enzyme elevations were more frequent at higher doses, and there was a dose-dependent increase in hepatic fat fraction.URL: https://clinicaltrials.gov; Unique identifier: NCT04516291.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
高贵梦露发布了新的文献求助10
1秒前
3秒前
4秒前
GL发布了新的文献求助10
4秒前
乐乐应助如意枫叶采纳,获得10
4秒前
5秒前
史念薇发布了新的文献求助10
5秒前
xixi完成签到 ,获得积分10
5秒前
7秒前
青野发布了新的文献求助10
9秒前
12秒前
13秒前
高贵梦露完成签到,获得积分10
13秒前
15秒前
17秒前
量子星尘发布了新的文献求助10
18秒前
如意枫叶发布了新的文献求助10
19秒前
19秒前
20秒前
20秒前
22秒前
23秒前
24秒前
赘婿应助GL采纳,获得10
24秒前
25秒前
25秒前
Archer宇完成签到,获得积分10
25秒前
狸花小喵发布了新的文献求助10
27秒前
科研废物完成签到 ,获得积分10
27秒前
28秒前
29秒前
30秒前
31秒前
33秒前
34秒前
潇湘雪月发布了新的文献求助10
35秒前
35秒前
36秒前
ding应助咩咩羊采纳,获得10
36秒前
37秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989263
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253814
捐赠科研通 3270066
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136